Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis

Table 5 Expression of prostate-specific membrane antigen in neovascularization of cholangiocellular carcinoma and its relationship with clinicopathological parameters

Clinicopathological parameters	No. of cases	Tumor PSMA-positive, n				P value
		0	1	2	3
Gender
Male	112	24	13	46	29	0.773
Female	91	18	29	38	6
Age of diagnosis
< 50	49	8	22	6	13	0.387
≥ 50	154	34	20	78	22
Mean (range)	57 (41-78)
Region
Urban	91	16	23	47	5	0.325
Country	112	26	19	37	30
HBsAg
+	140	29	26	69	16	0.990
-	63	13	16	15	19
Tumor size
< 5 cm	98	23	27	30	18	0.178
≥ 5 cm	105	19	15	54	17
Stage
pT1	14	5	3	4	2	0.293
pT2	105	23	21	49	12
pT3	21	5	5	7	4
pT4	63	9	13	24	17
Nodal status
N0	182	36	39	74	33	0.346
N1	21	6	3	10	2
Metastasis
M0	182	37	40	76	29	0.709
M1	21	5	2	8	6
UICC stage at diagnosis
I-II	112	32	26	38	16	0.002a, r = 0.211
III-IV	91	10	16	46	19
Tumor grading
I	75	24	18	28	5	0.001a, r = 0.253
II	72	15	18	35	6
III	56	3	6	21	5
All case	203	42	42	84	35

^aP < 0.01. HBsAg: Hepatitis B surface antigen; PSMA: Prostate-specific membrane antigen; r: Spearman r; UICC: Union for International Cancer Control.